BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Resveratrol in the management of obesity-related fatty liver disea
 se: a randomized\, double-blind\, placebo-controlled clinical trial
DTSTART:20121218T100000
DTEND:20121218T110000
DTSTAMP:20260916T220421Z
UID:1879ce5fac0751263e441b8d83b4175b4eb7715c9ccfd8ea579aa177
CATEGORIES:Conferences - Seminars
DESCRIPTION:Véronique CHACHAY\nAccredited Practising Dietitian\, MSc Nutr
 ition and Dietetics\, PhD candidate\nThe University of Queensland Diamanti
 na Institute -Metabolic medicine group\nResearch wing\, Princess Alexandra
  Hospital\, Ipswich Road\nBrisbane\, Qld 4102\, Australia\nWe investigated
  the efficacy of nutraceutical resveratrol on hepatic and cardiometabolic 
 dysregulation in 20 overweight/obese men with non-alcoholic fatty liver di
 sease (NAFLD)\, randomized to either 3000mg resveratrol (1500mg b.d.) or p
 lacebo daily for 8 weeks.\nPrimary outcome: Peripheral insulin resistance\
 , (euglycemic-hyperinsulinemic clamp).\nSecondary outcomes: Hepatic trigly
 cerides content and abdominal adipose tissue topography (magnetic resonanc
 e spectroscopy and imaging)\; plasma adiponectin (total and high molecular
 -weight)\; oxidative-stress and antioxidant capacity (isoprostanes\, TAC\,
  GPX\, FRAP\, SOD)\; inflammatory and liver biochemistry.\nConclusion: Des
 pite demonstrated prevention of NAFLD in animal models\, nutraceutical tra
 ns-resveratrol at this dosage\, over 8 weeks\, did not demonstrate apparen
 t clinical benefit in patients with well established NAFLD.
LOCATION:AI 1153 https://plan.epfl.ch/?room==AI%201153
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR